St Jude CE marks "less invasive" neurostimulation lead delivery system
This article was originally published in Clinica
St Jude Medical has CE marked its Epiducer lead delivery system, used to implant neurostimulation devices, for sale in Europe. Neurostimulation therapy is used to manage chronic pain, and involves implantation of a paddle lead in the epidural space near the spine. Mild electrical impulses are delivered from a neurostimulator to the leads' electrodes, to interrupt or mask pain signals to the brain. The new system allows physicians to implant paddle leads through a single percutaneous entry point – previously, this had to be done via laminotomy, a more invasive surgical procedure in which part of the spine typically has to be removed. St Jude (St Paul, Minnesota) markets several neurostimulation systems, including Genesis and Eon Mini.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.